Crispr Therapeutics AG Files $600M Share Offering

Crispr Therapeutics AG ( (CRSP) ) has issued an update.

On October 15, 2025, CRISPR Therapeutics AG announced the filing of a prospectus supplement with the SEC to offer and sell additional common shares worth up to $600 million through Jefferies LLC. This move aligns with the company’s strategic financial initiatives, potentially impacting its market position and stakeholder interests by providing additional capital for its operations and growth.

The most recent analyst rating on (CRSP) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Spark’s Take on CRSP Stock

According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.

Crispr Therapeutics AG’s overall stock score is primarily influenced by its financial performance, which is challenged by negative profitability and cash flow metrics. Technical analysis provides mixed signals, with some stability in short-term trends but bearish momentum. Valuation is hindered by the company’s current unprofitability. The absence of earnings call and corporate events data limits additional insights.

To see Spark’s full report on CRSP stock, click here.

More about Crispr Therapeutics AG

CRISPR Therapeutics AG operates in the biotechnology industry, focusing on the development of transformative gene-based medicines using CRISPR/Cas9 technology. The company is primarily engaged in creating therapies for serious diseases, leveraging its expertise in gene editing to address unmet medical needs.

Average Trading Volume: 2,881,786

Technical Sentiment Signal: Buy

Current Market Cap: $6.21B

For detailed information about CRSP stock, go to TipRanks’ Stock Analysis page.